In case you weren't able to attend this live panel discussion on #Type1Diabetes screenings put on by The Sugar Science, it's now available to view on YouTube: youtu.be/jZIFm9YoxWU?...

#T1DResearch #DiabetesHealth #T1D #MedicalResearch #health #healthcare #MD #physician #doctor #HCP #TrialNet

Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies - BMC Medicine Background Accurate type 1 diabetes prediction is important to facilitate screening for pre-clinical type 1 diabetes to enable potential early disease-modifying interventions and to reduce the risk of...

🚨Big news! Excited to share my first PhD paper!🎉
We validated & improved a T1D risk model using TrialNet data (originally from TEDDY), boosting accuracy 📈
bmcmedicine.biomedcentral.com/articles/10....
Try the web tool 👉 t1dpredictor.diabetesgenes.org
#T1D #RiskPrediction #PrecisionMedicine #TrialNet

Understand the Three Stages of Type 1 Diabetes

Type 1 diabetes staging classification opens door for intervention | #Type1Diabetes #TrialNet

www.trialnet.org/events-news/...

#T1D #diabetes #healthcare #health #DiabetesResearch

Type 1 diabetes staging classification opens door for intervention | Type 1 Diabetes TrialNet

Understand the Three Stages of #Type1Diabetes

Type 1 diabetes staging classification opens door for intervention | Type 1 Diabetes TrialNet > www.trialnet.org/events-news/...

#T1D #diabetes #TrialNet #healthcare #health #DiabetesResearch

New study analysing #TrialNet data to look at #T1D disease heterogeneity & response to #teplizumab #Diabetes #Endocrinology #DiabetesResearch

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab - Diabetologia Aims/hypothesis We aimed to analyse TrialNet Anti-CD3 Prevention (TN10) data using oral minimal model (OMM)-derived indices to characterise the natural history of stage 2 type 1 diabetes in placebo-tr...

Changes in insulin secretion & clearance predict progression in stage 2 type 1 diabetes & response to teplizumab. Oral-minimal model identifies disease heterogeneity in stage 2 #T1D link.springer.com/article/10.1... 🔓 #TrialNet #T1Dprevention